GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (FRA:LSRM) » Definitions » Loans Receivable

CEL-SCI (FRA:LSRM) Loans Receivable : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is CEL-SCI Loans Receivable?

CEL-SCI's Loans Receivable for the quarter that ended in Mar. 2024 was €0.00 Mil.


CEL-SCI Loans Receivable Historical Data

The historical data trend for CEL-SCI's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI Loans Receivable Chart

CEL-SCI Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CEL-SCI Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CEL-SCI Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


CEL-SCI Loans Receivable Related Terms

Thank you for viewing the detailed overview of CEL-SCI's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


CEL-SCI (FRA:LSRM) Business Description

Traded in Other Exchanges
Address
8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

CEL-SCI (FRA:LSRM) Headlines

No Headlines